((Chloroquine OR Hydroxychloroquine) AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
4,429 results
- Spectroscopic investigation and structural simulation in human serum albumin with hydroxychloroquine/Silybum marianum and a possible potential COVID-19 drug candidate. [Journal Article]Arch Pharm (Weinheim). 2024 Apr 21 [Online ahead of print]AP
- In this study, the interaction between human serum albumin (HSA) and the hydroxychloroquine/Silybum marianum (HCQ/SM) mixture was investigated using various techniques. The observed high binding constant (Kb) and Stern-Volmer quenching constant (KSV) indicate a strong binding affinity between the HCQ/SM mixture and HSA. The circular dichroism (CD) analysis revealed that HCQ/SM induced conformatio…
- Publisher Full Text (DOI)
- Enteric coronavirus nsp2 is a virulence determinant that recruits NBR1 for autophagic targeting of TBK1 to diminish the innate immune response. [Journal Article]Autophagy. 2024 Apr 16 [Online ahead of print]A
- Non-structural protein 2 (nsp2) exists in all coronaviruses (CoVs), while its primary function in viral pathogenicity, is largely unclear. One such enteric CoV, porcine epidemic diarrhea virus (PEDV), causes high mortality in neonatal piglets worldwide. To determine the biological role of nsp2, we generated a PEDV mutant containing a complete nsp2 deletion (rPEDV-Δnsp2) from a highly pathogenic s…
- Publisher Full Text (DOI)
- Incident use of hydroxychloroquine for the treatment of rheumatoid arthritis and systemic lupus erythematosus during the COVID-19 pandemic. [Journal Article]Arthritis Care Res (Hoboken). 2024 Mar 25 [Online ahead of print]AC
- CONCLUSIONS: Use of HCQ increased dramatically in the general population in both Spain and the US during March and April 2020. While Spain returned to pre-pandemic rates after the first wave, use of HCQ remained high and followed waves of COVID-19 in the US. However, we found no evidence of general shortages in the use of HCQ for both RA and SLE in the US. This article is protected by copyright. All rights reserved.
- Publisher Full Text (DOI)
- Quality-by-design ecofriendly potentiometric sensor for rapid monitoring of hydroxychloroquine purity in the presence of toxic impurities. [Journal Article]
- Hydroxychloroquine (HCQ) is prescribed to treat malaria and certain autoimmune diseases. Recent studies questioned its efficiency in relieving COVID-19 symptoms and improving clinical outcomes. This work presents a quality-by-design approach to develop, optimize, and validate a potentiometric sensor for the selective analysis of HCQ in the presence of its toxic impurities (key starting materials)…
- PMC Free PDF
- Premature Closure of Scientific Thinking: Deaths Due to Chloroquine and Hydroxychloroquine Used for COVID-19 Infection. [Journal Article]Am J Ther. 2024 Mar-Apr 01; 31(2):e186-e187.AJ
- Publisher Full Text (DOI)
- Association of the medication protocols and longitudinal change of COVID-19 symptoms: a hospital-based mixed-statistical methods study. [Journal Article]J Biopharm Stat. 2024 Mar 21 [Online ahead of print]JB
- The objective of this study was to identify the relationship between hospitalization treatment strategies leading to change in symptoms during 12-week follow-up among hospitalized patients during the COVID-19 outbreak. In this article, data from a prospective cohort study on COVID-19 patients admitted to Khorshid Hospital, Isfahan, Iran, from February 2020 to February 2021, were analyzed and repo…
- Publisher Full Text (DOI)
- Look after the COVID-19 pandemic: Mortality rates among patients with rheumatic diseases. [Journal Article]Int J Rheum Dis. 2024 Mar; 27(3):e15129.IJ
- CONCLUSIONS: COVID-19 is a serious infection and the current study emphasized that patients with rheumatic diseases had increased mortality rates, particularly in patients who were old, male, and on immunosuppressive treatments.
- Publisher Full Text (DOI)
- Drugs and natural products for the treatment of COVID-19 during 2020, the first year of the pandemic. [Journal Article]Bol Med Hosp Infant Mex. 2024; 81(1):53-72.BM
- This work aimed to show which treatments showed efficacy against coronavirus disease 2019 (COVID-19); therefore, the results of 37 clinical trials started in 2020 and completed in 2021 are reviewed and discussed here. These were selected from databases, excluding vaccines, computational studies, in silico, in vitro, and those with hyperimmune sera from recovered patients. We found 34 drugs, one v…
- Publisher Full Text (DOI)
- COVID-19 in patients with Down syndrome: A systematic review. [Systematic Review]
- CONCLUSIONS: More studies are needed to better understand COVID-19 infections among persons with DS. In addition, the study was limited by a lack of statistical analyses and a specific comparison group.
- PMC Free PDF
- Interferon Upregulation Associates with Insulin Resistance in Humans. [Journal Article]Curr Diabetes Rev. 2024 Mar 18 [Online ahead of print]CD
- In humans, insulin resistance is a physiological response to infections developed to supply sufficient energy to the activated immune system. This metabolic adaptation facilitates the immune response but usually persists after the recovery period of the infection and predisposes the hosts to type 2 diabetes and vascular injury. In patients with diabetes, superimposed insulin resistance worsens me…
- Publisher Full Text (DOI)
- Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19. [Journal Article]
- CONCLUSIONS: This study primarily investigated the effect of treatment and vaccination on the prognosis of COVID-19. This was determined to be prepared for another potential pandemic that may arise due to COVID-19.
- Publisher Full Text (DOI)
- Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know. [Review]J Dermatol. 2024 Mar 14 [Online ahead of print]JD
- Antimalarials (AMs), particularly hydroxychloroquine (HCQ) and chloroquine (CQ), are the cornerstone of the treatment for both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). HCQ and CQ are recommended as first-line oral agents in all CLE guidelines. Initially thought to have potential therapeutic effects against COVID-19, HCQ has drawn significant attention in recent …
- Publisher Full Text (DOI)
- Characteristics and Outcomes of Stem Cell Transplant Patients during the COVID-19 Era: A Systematic Review and Meta-Analysis. [Review]
- This systematic review and meta-analysis aims to identify the outcomes of stem cell transplant (SCT) patients during the COVID-19 era. Pooled event rates (PER) were calculated, and meta-regression was performed. A random effects model was utilized. In total, 36 eligible studies were included out of 290. The PER of COVID-19-related deaths and COVID-19-related hospital admissions were 21.1% and 55.…
- Publisher Full Text (DOI)
- Acro-Ischemia Associated With SARS-CoV-2: A Case Report. [Case Reports]Cureus. 2024 Feb; 16(2):e53798.C
- COVID-19 is known to cause various cutaneous lesions, including acro-ischemic lesions (AIL), which are associated with poor prognosis. Anticoagulant therapy has shown positive responses in AIL patients. However, in this case study, we present a fatal AIL case despite anticoagulant therapy. We propose different treatment approaches based on the limited current data on acro-ischemia pathogenesis re…
- PMC Free PDF
- BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir. [Journal Article]
- Viral RNA-dependent RNA polymerase (RdRp), a highly conserved molecule in RNA viruses, has recently emerged as a promising drug target for broad-acting inhibitors. Through a Vero E6-based anti-cytopathic effect assay, we found that BPR3P0128, which incorporates a quinoline core similar to hydroxychloroquine, outperformed the adenosine analog remdesivir in inhibiting RdRp activity (EC50 = 0.66 µM …
- PMC Free PDF
- Impact of COVID-19 Medication (Favipiravir and Hydroxychloroquine) on High Frequency Hearing. [Journal Article]
- During the initial phase of the COVID-19 pandemic, there was ongoing investigation into potentially effective treatments. Antiviral medications such as Favipiravir and Hydroxychloroquine were employed to treat COVID-19 infections. However, limited studies have examined the adverse effects of these medications on hearing, particularly at extended high frequencies. This study included 10 subjects w…
- Publisher Full Text (DOI)
- Improved fluorescence-based assay for rapid screening and evaluation of SARS-CoV-2 main protease inhibitors. [Journal Article]J Med Virol. 2024 Mar; 96(3):e29498.JM
- The outbreak of coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global threat to human health. In parallel with vaccines, efficacious antivirals are urgently needed. SARS-CoV-2 main protease (Mpro) is an attractive drug target for antiviral development owing to its key roles in virus replication and host immune evasion. …
- Publisher Full Text (DOI)
- Characteristics and risk factors of COVID-19 breakthrough infections in Idiopathic Inflammatory Myopathies: Results from the COVAD study. [Journal Article]Rheumatology (Oxford). 2024 Mar 02 [Online ahead of print]R
- CONCLUSIONS: Patients with IIMs are susceptible to severe COVID-19 BI. Age and immunosuppressive treatments were related to the risk of BIs.
- Publisher Full Text (DOI)
- Effect of Hydroxychloroquine and Azithromycin Combination Use in COVID-19 Patients - An Umbrella Review. [Review]
- CONCLUSIONS: Rampant use of Chloroquine or Hydroxychloroquine alone or with Azithromycin combination caused adverse effects like QT prolongation. Finally, there is no evidence to support use of either Hydroxychloroquine with or without Azithromycin, for the treatment of COVID-19.
- PMC Free PDF
- Inefficacious drugs against covid-19: analysis of sales, tweets, and search engines. [Journal Article]Rev Saude Publica. 2024; 58:06.RS
- CONCLUSIONS: The results contribute to decision making in crisis management by governments, industries, and stores. In times of crisis, as observed during the covid-19 pandemic, some variables can help sales forecasting, especially Google® and tweets, which provide a real-time analysis of the situation. Monitoring social media platforms and search engines would allow the determination of drug use by the population and better prediction of potential peaks in the demand for these drugs.
- Publisher Full Text (DOI)
- Disease-Modifying Medications in Patients with Rheumatoid Arthritis in the USA: Trends from 2016 to 2021. [Journal Article]
- CONCLUSIONS: About half of patients with RA were on DMARDs. As expected, csDMARDs were highly used consistently. The COVID-19 pandemic might have influenced the use of HCQ and infusion DMARDs. Triple therapy use remains low.
- Publisher Full Text (DOI)
- Efficient adsorptive removal of used drugs during the COVID-19 pandemic from contaminated water by magnetic graphene oxide/MIL-88 metal-organic framework/alginate hydrogel beads. [Journal Article]Chemosphere. 2024 Mar; 352:141397.C
- Currently, the presence of drugs used in the COVID-19 pandemic in water bodies is worrisome due to their high toxicity, which necessitates their critical removal by developing highly efficient adsorbents. Hence, in this study, alginate hydrogel beads of magnetic graphene oxide@MIL-88 metal-organic framework (GO@Fe3O4@MIL-88@Alg) were prepared for the first time and then utilized as a new absorpti…
- Publisher Full Text (DOI)
- Factors affecting different COVID-19 outcomes in patients with systemic lupus erythematosus during the second pandemic wave of COVID-19 in China. [Journal Article]Lupus. 2024 Apr; 33(4):357-364.L
- CONCLUSIONS: Different COVID-19 outcomes in people with SLE are mostly driven by COVID-19 vaccination, medications, and activity SLE. More importantly, three doses of COVID-19 vaccination may be associated with better outcomes.
- Publisher Full Text (DOI)
- FACTORS AFFECTING PROGNOSIS AND MORTALITY IN SEVERE COVID-19 PNEUMONIA PATIENTS. [Journal Article]
- Fatality rate in coronavirus disease 2019 (COVID-19) cases has been reported to be 3.4% worldwide. The aim of this study was to evaluate the factors that determine prognosis and mortality in severe COVID-19 pneumonia patients. Eighty adult patients with severe COVID-19 pneumonia hospitalized and monitored at Izzet Baysal State Hospital (Bolu, Turkey) between August and November 2020 were included…
- PMC Free PDF
- Coagulopathy and adverse outcomes in hospitalized patients with COVID-19: results from the NOR-Solidarity trial. [Journal Article]
- CONCLUSIONS: TFPI and tPA are associated with severe disease in hospitalized patients with COVID-19. For TFPI, high levels measured during the first 10 days of hospitalization were also associated with persistent pulmonary pathology even 3 months after hospital admittance.
- PMC Free PDF
- [Hydroxychloroquine-not always a harmless drug for off label use in dermatology]. [Journal Article]
- Hydroxychloroquine is used for treatment of inflammatory diseases. It is considered to have few adverse effects. We report on a woman who developed a severe skin rash after intake of hydroxychloroquine, which she received for treatment of her lichen planopilaris. Based on the clinical, laboratory and histological findings the diagnosis of a drug reaction with eosinophilia and systemic symptoms (D…
- Publisher Full Text (DOI)
- Campesterol and dithymoquinone as a potent inhibitors of SARS cov-2 main proteases-promising drug candidates for targeting its novel variants. [Journal Article]J Biomol Struct Dyn. 2024 Jan 30 [Online ahead of print]JB
- The sudden outbreak of the COVID-19 pandemic has currently taken approximately 2.4 million lives, with no specific medication and fast-tracked tested vaccines for prevention. These vaccines have their own adverse effects, which have severely affected the global healthcare system. The discovery of the main protease structure of coronavirus (Mpro/Clpro) has resulted in the identification of compoun…
- Publisher Full Text (DOI)
- A comprehensive review of Langya virus and framework for future zoonotic disease control. [Review]Rev Med Virol. 2024 Jan; 34(1):e2520.RM
- First reported in August 2022, the Langya virus (LayV) has emerged as a potential global health threat in the post-COVID-19 era. Preliminary reports show that 35 patients near Shandong and Henan, China experienced a febrile acute LayV infection. We conducted this review following the PRISMA protocol to synthesise current knowledge on LayV's characteristics in terms of molecular, clinical, and pub…
- Publisher Full Text (DOI)
- Editor's Note on "Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: An estimate" [Biomed. Pharmacother. 171 (2024) 116055]. [Editorial]Biomed Pharmacother. 2024 Feb; 171:116183.BP
- Publisher Full Text (DOI)